🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: FF MDI

Found 37 matching trials

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

The purpose of this study is to evaluate the efficacy of Fixed Combination ...

Status

Completed

Location

Medical Center Convex EOOD

Start Date

2018-06-15

Trial ID

NCT03590379

Treatments Being Tested

CHF 5993 DPI CHF5993 pMDI CHF 1535 pMDI Placebo DPI Placebo pMDI

BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)

PHASE3

a 48-week, 2-arm parallel group, "fixed combination" beclomethasone dipropi...

Status

Completed

Location

UCL Medical School

Start Date

2009-10

Trial ID

NCT00929851

Treatments Being Tested

CHF1535 Formoterol fumarate

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

PHASE3

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA...

Status

Completed

Location

GSK Investigational Site

Start Date

2016-10-13

Trial ID

NCT02924688

Treatments Being Tested

FF/UMEC/VI (100/31.25/25) mcg FF/UMEC/VI (100/62.5/25) mcg FF/UMEC/VI (200/31.25/25) mcg FF/UMEC/VI (200/62.5/25) mcg FF/VI (100/25) mcg FF/VI (200/25) mcg Fluticasone/salmeterol (FSC)Albuterol/salbutamol ELLIPTA DPI DISKUS DPI METERED-DOSE INHALER (MDI)

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

PHASE1

The study is being conducted to compare the pharmacokinetic (PK) of BDP (an...

Status

Completed

Location

SGS Belgium NV - Clinical Pharmacology Unit

Start Date

2023-04-24

Trial ID

NCT05898984

Treatments Being Tested

Test product (T):CHF 5993 BDP/FF/GB 200/6/12.5 µg pMDI Reference product 1 (R1): CHF 5993 BDP/FF/GB 100/6/12.5 µg pMDI Reference product 2 (R2): BDP HFA (QVAR REDIHALER®, BDP 80 μg)

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD

PHASE4

Double Blind, Multinational, Multicentre, Randomised, Placebo-Controlled, 3...

Status

Completed

Location

PAREXEL International GmbH Early Phase Clinical Unit Berlin

Start Date

2021-10-28

Trial ID

NCT05097014

Treatments Being Tested

CHF5993 CHF1535 Matched placebo

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE4

The primary purpose of this study is to evaluate lung function and health r...

Status

Completed

Location

GSK Investigational Site

Start Date

2018-06-25

Trial ID

NCT03478696

Treatments Being Tested

budesonide/formoterol albuterol/salbutamol FF/UMEC/VI Placebo to match budesonide/formoterol tiotropium Placebo to match FF/UMEC/VI placebo to match tiotropium ELLIPTA MDI HandiHaler

Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients

PHASE3

Primary objective To show the superiority of CHF 1535 (BDP/FF) pMDI (800/2...

Status

Completed

Location

Chiesi Clinical Trial Site

Start Date

2012-04-20

Trial ID

NCT01577082

Treatments Being Tested

CHF1535 200/6 µg pMDI BDP HFA 100 µg pMDI

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

PHASE3

This is a Phase III randomized, double-blind, parallel group, multi-center,...

Status

Completed

Location

Research Site

Start Date

2016-05-31

Trial ID

NCT02766608

Treatments Being Tested

BFF MDI 320/9.6 μg BFF MDI 160/9.6 μg FF MDI 9.6 μg BD MDI 320 μg Symbicort® TBH 400/12 μg BID

Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)

N/A

The purpose of the study is to evaluate Real-World Effectiveness of a Tripl...

Status

Completed

Location

Site 156119 - Peking University People's Hospital

Start Date

2024-07-02

Trial ID

NCT06480890

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

PHASE2

This study is conducted to evaluate the effects of UMEC 62.5 microgram (mcg...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-01-25

Trial ID

NCT03012061

Treatments Being Tested

Placebo UMEC Fluticasone Furoate Albuterol/salbutamol

Previous Next